4 Results for "

sickle cell disease models

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "sickle cell disease models" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-139400
CAS No.: 2490676-18-9
Purity:  99.97%
Synonyms: FTX-6058
Research Areas:  

Cardiovascular Disease

Pociredir (FTX-6058) is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir can induce HbF protein expression in cell and murine models. Pociredir can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139400A
CAS No.: 2490676-19-0
Purity:  99.89%
Synonyms: FTX-6058 hydrochloride
Research Areas:  

Cardiovascular Disease

Pociredir (FTX-6058) hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir hydrochloride can induce HbF protein expression in cell and murine models. Pociredir hydrochloride can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .
loading...
    loading...
Cat. No.: HY-159098
dWIZ-1 is an orally active molecular glue and chemical probe targeting the WIZ transcription factor, which based on an IMiD backbone, binding to human WIZ with an affinity of 3.5 μM. dWIZ-1 recruits WIZ to the cereblon-DDB1 complex via its ZF7 domain, thereby triggering proteasome-dependent degradation of WIZ. dWIZ-1 significantly induces fetal hemoglobin expression in erythroblasts while reducing the level of inhibitory H3K9 dimethylation at WIZ binding sites such as the β-globin locus. Meanwhile, dWIZ-1 does not affect the proliferation and differentiation of erythroblasts, and no cytotoxicity is observed in in vitro cells or cynomolgus monkey models. dWIZ-1 serves as a critical tool molecule for investigating the mechanism and underlying pathways of sickle cell disease .
loading...
    loading...
Cat. No.: HY-135146A
CAS No.: 2170136-02-2
Purity:  99.43%
Synonyms: GSK3482364
Target:  

DNA Methyltransferase

Research Areas:  

Cancer

(Rac)-GSK-3484862 (GSK3482364) is a selective, orally active, reversible DNA methyltransferase 1 (DNMT1) inhibitor with an IC50 of 0.4 μM. (Rac)-GSK-3484862 inhibits the methyltransferase activity of DNMT1 independently of DNA incorporation, reduces global DNA methylation levels, and relieves the transcriptional repression of HBG1 and HBG2 genes. (Rac)-GSK-3484862 increases fetal hemoglobin levels and the proportion of red blood cells expressing fetal hemoglobin in erythroid progenitor cells and a transgenic mouse model of sickle cell disease. (Rac)-GSK-3484862 can be used in studies related to sickle cell disease .
loading...
    loading...